BACKGROUND: For > 20 years, pharmaceutical companies and academic centers have been developing bradykinin antagonists. The patent literature on these molecules (up to and including 2004) has been analyzed previously in this journal in two review articles. OBJECTIVE: The aim of this review is to provide an update (from 2005 to early 2009) on the patenting activity in the field of bradykinin antagonists (including patents on their formulation). Where possible, the information from the patents has been supplemented with that from the primary literature, clinical trial databases and company websites in an attempt to give a more complete picture. CONCLUSIONS: In the past 4 years, nearly 50 new patents have been filed on bradykinin antagonists--in the case of several filings, only the original source has been considered in this analysis--the vast majority of these (> 93%) on B1 antagonists. However, despite this large amount of work, only one compound, icatibant--a hydrophilic decapeptide selective for the B2 receptor--has reached the market, although it needs to be administered parenterally.
BACKGROUND: For > 20 years, pharmaceutical companies and academic centers have been developing bradykinin antagonists. The patent literature on these molecules (up to and including 2004) has been analyzed previously in this journal in two review articles. OBJECTIVE: The aim of this review is to provide an update (from 2005 to early 2009) on the patenting activity in the field of bradykinin antagonists (including patents on their formulation). Where possible, the information from the patents has been supplemented with that from the primary literature, clinical trial databases and company websites in an attempt to give a more complete picture. CONCLUSIONS: In the past 4 years, nearly 50 new patents have been filed on bradykinin antagonists--in the case of several filings, only the original source has been considered in this analysis--the vast majority of these (> 93%) on B1 antagonists. However, despite this large amount of work, only one compound, icatibant--a hydrophilic decapeptide selective for the B2 receptor--has reached the market, although it needs to be administered parenterally.
Authors: Marco Cicardi; Aleena Banerji; Francisco Bracho; Alejandro Malbrán; Bernd Rosenkranz; Marc Riedl; Konrad Bork; William Lumry; Werner Aberer; Henning Bier; Murat Bas; Jens Greve; Thomas K Hoffmann; Henriette Farkas; Avner Reshef; Bruce Ritchie; William Yang; Jürgen Grabbe; Shmuel Kivity; Wolfhart Kreuz; Robyn J Levy; Thomas Luger; Krystyna Obtulowicz; Peter Schmid-Grendelmeier; Christian Bull; Brigita Sitkauskiene; William B Smith; Elias Toubi; Sonja Werner; Suresh Anné; Janne Björkander; Laurence Bouillet; Enrico Cillari; David Hurewitz; Kraig W Jacobson; Constance H Katelaris; Marcus Maurer; Hans Merk; Jonathan A Bernstein; Conleth Feighery; Bernard Floccard; Gerald Gleich; Jacques Hébert; Martin Kaatz; Paul Keith; Charles H Kirkpatrick; David Langton; Ludovic Martin; Christiane Pichler; David Resnick; Duane Wombolt; Diego S Fernández Romero; Andrea Zanichelli; Francesco Arcoleo; Jochen Knolle; Irina Kravec; Liying Dong; Jens Zimmermann; Kimberly Rosen; Wing-Tze Fan Journal: N Engl J Med Date: 2010-08-05 Impact factor: 91.245
Authors: S Meini; F Bellucci; C Catalani; P Cucchi; A Giolitti; S Giuliani; L Quartara; L Rotondaro; S Zappitelli; C A Maggi Journal: Br J Pharmacol Date: 2011-03 Impact factor: 8.739